Determination of imatinib intracellular uptake in leukocytes as a prognostic factor in cML therapy

Determination of imatinib intracellular uptake in leukocytes as a prognostic factor in cML therapy

Background: Imatinib is the first target therapy for chronic myelogenous leukemia (CML). Response to imatinib treatment also depends on the uptake of the drug into the target cell by organic cation transporter 1 (OCT1). OCT1 activity determined by the uptake of 14C-imatinib (IUR) in isolated mon...

Full description

Bibliographic Details
Main Authors:	Eva Kralj, Simon Žakelj, Jurij Trontelj, Katja Berginc, Tadej Pajić, Irena Preložnik Zupan, Peter Černelč, Barbara Ostanek, Helena Podgornik, Janja Marc, Albin Kristl
Format:	Article
Language:	English
Published:	Slovenian Medical Association 2012-12-01
Series:	Zdravniški Vestnik
Online Access:	http://vestnik.szd.si/index.php/ZdravVest/article/view/757

Similar Items

Imatinib plasma concentration – a new laboratory parameter for monitoring the treatment of Slovenian patients with chronic myeloid leukemia
by: Jernej Mlakar, et al.
Published: (2011-03-01)

SMERNICE ZA ODKRIVANJE IN ZDRAVLJENJE KRONIČNEMIELOIČNE LEVKEMIJE
by: Irena Preložnik Zupan, et al.
Published: (2008-04-01)

Bcr-aBL1 kinase domain mutation analysis in chronic myeloid leukaemia patients with suboptimal response to tyrosine kinase inhibitors
by: Tadej Pajič, et al.
Published: (2012-12-01)

CML treatment results in Slovenia in the era of tirozin kinaze inhibitors
by: Irena Preložnik Zupan, et al.
Published: (2012-12-01)

Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way
by: Berginc Katja, et al.
Published: (2020-06-01)

Slovenian recommendations for the management of chronic myeloid leukaemia
by: Irena Preložnik Zupan, et al.
Published: (2018-04-01)

Identification of Variants Associated With Rare Hematological Disorder Erythrocytosis Using Targeted Next-Generation Sequencing Analysis
by: Aleša Kristan, et al.
Published: (2021-07-01)

Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
by: Ali M. Jawad, et al.
Published: (2008-10-01)

MUTATIONAL STATUS OF REARRANGED IMMUNOGLOBULIN HEAVY CHAINVARIABLE GENES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
by: Tadej Pajič, et al.
Published: (2008-04-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-04-01)

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
by: Winter, Georg E, et al.
Published: (2014)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-01-01)

PDGFR-β mediated growth failure in pediatric CML cases on Imatinib
by: Prakamya Gupta, et al.
Published: (2020-09-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2019-10-01)

THE ROLE OF CYTOGENETICS AND MOLECULAR GENETICS IN DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA AND MONITORING OF TREATMENT RESPONSE
by: Helena Podgornik, et al.
Published: (2004-12-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure
by: Cervera Eduardo, et al.
Published: (2007-02-01)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)

Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations
by: Nadica Sibinovska, et al.
Published: (2022-02-01)

DETECTION OF SPECIFIC CHROMOSOMAL REARRANGEMENT IN LEUKEMIA PATIENTS BY mDx HEMAVISION KIT
by: Tadej Pajič, et al.
Published: (2004-12-01)

Paroxysmal nocturnal hemoglobinuria – first treatment experience with eculizumab in Slovenian patients
by: Irena Preložnik Zupan
Published: (2012-12-01)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
by: Trdan Lušin Tina, et al.
Published: (2012-04-01)

Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients
by: Ehsan Mohajeri, et al.
Published: (2016-02-01)

Imatinib improves survival of CML patients in accelerated phase: A 48-month follow-up
by: Juliana Todaro, et al.
Published: (2006-03-01)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
by: Miwako Narita, Masayoshi Masuko, Tohri Kurasaki, Toshiki Kitajima, Shoko Takenouchi, Anri Saitoh, Norihiro Watanabe, Tatsuo Furukawa, Ken Toba, Ichiro Fuse, Yoshifusa Aizawa, Manabu Kawakami, Yoshihiro Oka, Haruo Sugiyama, Masuhiro Takahashi
Published: (2010-01-01)

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
by: Karla Rener, et al.
Published: (2023-11-01)

Comparison of erythrocyte and reticulocyte indices for the diagnosis of iron defciency
by: Eva Jarc, et al.
Published: (2017-03-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
by: Hamza MS, et al.
Published: (2022-05-01)

CHRONIC MYELOID LEUKAEMIA: EPIDEMIOLOGY DATA (2002–2007)
by: Irena Preložnik Zupan, et al.
Published: (2008-04-01)

Is It Possible to Predict Clonal Thrombocytosis in Triple-Negative Patients with Isolated Thrombocytosis Based Only on Clinical or Blood Findings?
by: Tanja Belčič Mikič, et al.
Published: (2021-12-01)

Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML
by: Zilin Li, et al.
Published: (2024-04-01)

Nilotinib efficacy and safety in CML patient with Parossistic Sopraventricular Tachycardia (PSVT), after sub-optimal response to imatinib
by: Stefana Impera, et al.
Published: (2015-10-01)

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
by: Clara I Aceves-Luquero, et al.
Published: (2009-07-01)

Nilotinib early switch efficacy in non-optimal responder CML patient after first line imatinib treatment
by: Ferdinando Porretto
Published: (2015-10-01)

CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML
by: An-Ni Zhong, et al.
Published: (2021-09-01)

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH ACUTE LEUKEMIA – 14 YEARS EXPERIENCE
by: Jože Pretnar, et al.
Published: (2004-12-01)